Skip Navigation

European Heart Journal 1990 11(Supplement A):27-31; doi:10.1093/eurheartj/11.suppl_A.27
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Katz, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katz, A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Inotropic and lusitropic abnormalities in heart failure

A. M. Katz

Cardiology Division, Department of Medicine, University of Connecticut Farmington, U.S.A.

Address for correspondence: Professor A. M. Katz, Cardiology Division, Department of Medicine, University of Connecticut, Farmington, CT 06032, U S.A.

Impaired pump function in the patient with congestive heart failure can arise from both contraction (inotropic) and relaxation (lusitropic) abnormalities. Because energy is required for both contraction and relaxation, evidence that the failing heart is in an energy-starved state may explain, at least in part, these functional abnormalities. The relative contributions of inotropic and lusitropic abnormalities to clinical disability differ in individual patients with heart failure, so that therapy of heart failure must be tailored to the specific pathophysiology that operates in each patient.

Key Words: Congestive heart failure • inotropic • lusitropic abnormalities


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. M. Tsimberidou, L. H. Camacho, S. Verstovsek, C. Ng, D. S. Hong, C. K. Uehara, C. Gutierrez, S. Daring, J. Stevens, P. B. Komarnitsky, et al.
A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors
Clin. Cancer Res., July 15, 2009; 15(14): 4769 - 4776.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. J. Rademacher, S. Patel, W.-S. V. Ho, A. M. Savoie, N. J. Rusch, K. M. Gauthier, and C. J. Hillard
U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2694 - H2701.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. M. Metzger and M. V. Westfall
Covalent and Noncovalent Modification of Thin Filament Action: The Essential Role of Troponin in Cardiac Muscle Regulation
Circ. Res., February 6, 2004; 94(2): 146 - 158.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. J. Zeitz, D. J. Campbell, and J. D. Horowitz
Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans
Hypertension, March 1, 2003; 41(3): 482 - 487.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.